Moreover, RRx-001 (Figure 8) is an anticancer drug candidate in phase III clinical trials, which inhibits CD47 expression and polarizes tumor-associated macrophages from a low phagocytic M2 phenotype to a high phagocytic M1 phenotype [144]. Here, CD47 is linked to neoplasm.